An antibiotic stewardship program blueprint for optimizing verigene bc-gn within an institution: A tale of two cities
JournalAntimicrobial Agents and Chemotherapy
PublisherAmerican Society for Microbiology
MetadataShow full item record
AbstractRapid diagnostic tests (RDTs) have revolutionized the management of Gram-negative bacteremia by allowing antimicrobial stewardship teams the ability to escalate therapy and improve patient outcomes through timely organism identification and detection of certain resistance determinants. However, given the complex nature of Gram-negative resistance, stewardship teams are left without clear direction for how to respond when resistance determinants are absent, as the safety of de-escalation in this setting is unknown. The primary purpose of this analysis was to determine the negative predictive values (NPVs) of resistance marker absence for predicting susceptibility in target bug-drug scenarios at two geographically distinct institutions. A total of 1,046 Gram-negative bloodstream isolates that were analyzed with the Verigene BC-GN platform were assessed. Except for Pseudomonas aeruginosa, the absence of resistance determinants as reported by the RDT largely predicted susceptibility to target antibiotics at both institutions. NPVs for ceftriaxone susceptibility in Escherichia coli and Klebsiella pneumoniae in the absence of either CTX-M or a carbapenemase gene were 98% and 93 to 94%, respectively. Similar results were seen with other target bug-drug scenarios, with NPVs of 94 to 100% demonstrated at both institutions, with the exception of P. aeruginosa, for which NPVs were poor, likely due to the more complex nature of resistance in this pathogen. The results of this study show that clinicians at both institutions should have confidence in de-escalation in the absence of resistance determinant detection by Verigene BC-GN testing, and the methodology described within this article can serve as a blueprint for other stewardship programs to employ at their institutions to optimize management of Gram-negative bacteremia. Copyright Copyright 2018 American Society for Microbiology. All Rights Reserved.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85046030934&doi=10.1128%2fAAC.02538-17&partnerID=40&md5=5eee88f016e17baef3eac203ac99d4bf; http://hdl.handle.net/10713/9246
- Rapid testing using the Verigene Gram-negative blood culture nucleic acid test in combination with antimicrobial stewardship intervention against Gram-negative bacteremia.
- Authors: Bork JT, Leekha S, Heil EL, Zhao L, Badamas R, Johnson JK
- Issue date: 2015 Mar
- Pediatric multicenter evaluation of the Verigene gram-negative blood culture test for rapid detection of inpatient bacteremia involving gram-negative organisms, extended-spectrum beta-lactamases, and carbapenemases.
- Authors: Sullivan KV, Deburger B, Roundtree SS, Ventrola CA, Blecker-Shelly DL, Mortensen JE
- Issue date: 2014 Jul
- Impact of antimicrobial stewardship and rapid microarray testing on patients with Gram-negative bacteremia.
- Authors: Rivard KR, Athans V, Lam SW, Gordon SM, Procop GW, Richter SS, Neuner E
- Issue date: 2017 Oct
- Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia.
- Authors: Perez KK, Olsen RJ, Musick WL, Cernoch PL, Davis JR, Peterson LE, Musser JM
- Issue date: 2014 Sep
- [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
- Authors: Gür D, Gülay Z, Akan OA, Aktaş Z, Kayacan CB, Cakici O, Eraç B, Gültekin M, Oğünç D, Söyletir G, Unal N, Uysal S
- Issue date: 2008 Oct